Liontrust Investment Partners LLP Decreases Stake in iRadimed Corporation $IRMD

Liontrust Investment Partners LLP reduced its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 41.7% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 21,255 shares of the medical equipment provider’s stock after selling 15,216 shares during the quarter. Liontrust Investment Partners LLP’s holdings in iRadimed were worth $2,046,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in shares of iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares during the period. Quarry LP acquired a new position in iRadimed in the 3rd quarter worth approximately $40,000. CWM LLC increased its holdings in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 107 shares during the period. Tower Research Capital LLC TRC raised its position in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in iRadimed during the 4th quarter worth approximately $85,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Stock Performance

NASDAQ IRMD opened at $90.86 on Friday. The stock has a 50-day simple moving average of $94.54 and a two-hundred day simple moving average of $95.70. The firm has a market capitalization of $1.16 billion, a P/E ratio of 49.65 and a beta of 0.90. iRadimed Corporation has a fifty-two week low of $57.83 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, analysts forecast that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $120.00.

Trending Headlines about iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the sale, the chief executive officer owned 2,175,000 shares in the company, valued at approximately $190,334,250. This represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,250 shares of company stock valued at $1,836,403 over the last three months. Insiders own 34.60% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.